Enriqueta Felip, MD, PhD, discusses the design of the phase 3 3475A-D77 trial evaluating subcutaneous pembrolizumab in metastatic NSCLC.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the ...

In a live virtual event, Thomas C. Krivak, MD, reviewed the key studies of PARP inhibitor and bevacizumab maintenance in ...

During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in ...

Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

A regimen based on Roche's CD20xCD3 bispecific antibody Columvi has been approved in the EU as a second-line therapy for ...

The "Keytruda Market Size, Share & Trends Analysis Report By Application (Lung Cancer, Breast Cancer, Melanoma, Hodgkin Lymphoma), By Payer (Commercial/Private, Public), By Distribution Channel, By ...

Exact Sciences (EXAS) announced the publication of a comprehensive review in JAMA Oncology that strengthens the evidence supporting the ...

The 43-year-old reality star has stage IV melanoma, which has spread to her brain and lungs, and Teddi has been asking her doctors about her survival chances Teddi said on 'Nightline': "It's one of my ...

Oncology Clinical Trials Market has been steadily growing over the years due to increasing incidence of cancer, advancements ...

What was Val Kilmer's net worth at the time of his death? Dive into his career earnings and understand the financial story ...

When the Biden administration issued its final rule related to federally imposed minimum staffing requirements for long-term care facilities ...